List view / Grid view
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
Researchers have discovered that Alzheimer’s may disrupt communication between nerves and blood vessels in fat tissue which could explain why people with Alzheimer’s are often diagnosed with heart disease and metabolic problems.
Researchers have discovered that removing a telomere-protecting protein, TRF1, makes mice leaner and metabolically healthier without shortening their telomeres, potentially leading to new methods for tackling obesity and age-related diseases.
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
Scientists have developed a compound blend that reverses sugar-related cellular damage in mice, which could lead to future therapies to slow ageing and treat metabolic diseases.
Scientists have linked rare mutations in SPNS1 to a previously unknown lipid recycling pathway in lysosomes, revealing how faulty fat processing can trigger muscle and liver disease.
Scientists have discovered the molecular ‘switch’ that powers sperm for fertilisation, which could potentially lead to new infertility treatments.
A first-in-class obesity drug, presented at the European Association for the Study of Diabetes meeting in Vienna, aims to reprogramme metabolism rather than suppress appetite – offering the potential for long-lasting weight loss without regain.
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.
In the fight against antibiotic-resistant bacteria, researchers at Michigan State University (MSU) have made a discovery that could change how we target deadly pathogens like Staphylococcus aureus and its drug-resistant strain - MRSA.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 2, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
